CRISPR in the North American popular press
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
PURPOSE: CRISPR is often called one of the century's most important discoveries and is commonly discussed in terms of its momentous potential impacts. This study analyzed how CRISPR is discussed in the North American popular press, including how it is defined, and which benefits and risks/concerns are attributed to the technology. METHODS: Using the Factiva database, we identified 228 relevant, nonduplicated articles containing either "CRISPR" or "C.R.I.S.P.R.," published in popular US and Canadian news sources between 1 January 2012 and 12 July 2017. Content analysis was performed on the articles. RESULTS: CRISPR is most often discussed in the context of human health (83.8%), compared with animals (26.3%) and plants (20.6%). Nearly all articles (96.1%) presented CRISPR's potential benefits; 61.4% of articles presented CRISPR-related risks/concerns, the vast majority of which focused on the uncertainty surrounding CRISPR, specifically with respect to germline modifications. CONCLUSIONS: Overall, the discourse suggests a strong promotion of CRISPR, but an element of caution is also evident. Technical as well as ethical, legal, and social risks/concerns play a prominent role. This media portrayal of CRISPR might help facilitate more sophisticated and balanced policy responses, where the scientific potential of the technology is highlighted alongside broader social considerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A notable feature of these exchanges, especially evident in the news media, is the frequent failure to mention existing policies (legislation, regulations, guidelines, codes, and international treaties) that govern research involving human genome editing.12”
From Human Germline and Heritable Genome Editing: The Global Policy Landscape (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Three Approaches to Qualitative Content Analysis
Hsieh, H.-F., & Shannon, S. E. (2005) · Qualitative Health Research · doi:10.1177/1049732305276687 · Cited by 44,601
Interrater reliability: The kappa statistic
McHugh, M. L. (2012) · Biochemia Medica · doi:10.11613/bm.2012.031 · Cited by 19,877
Lippa, N. C., & Sanderson, S. C. (2013) · Human Heredity · doi:10.1159/000353712 · Cited by 6,078
Applications of CRISPR technologies in research and beyond
Barrangou, R., & Doudna, J. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3659 · Cited by 1,005
CRISPR germline engineering—the community speaks
Bosley, K., Botchan, M. R., Bredenoord, A. L., Carroll, D., Charo, R. A., Charpentier, E., Cohen, R., Corn, J. E., Doudna, J. A., Feng, G., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3227 · Cited by 141
As Gelsinger Case Ends, Gene Therapy Suffers Another Blow
Couzin, J., & Kaiser, J. (2005) · Science · doi:10.1126/science.307.5712.1028b · Cited by 140
Stem cell hype: Media portrayal of therapy translation
Kamenova, K., & Caulfield, T. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010496 · Cited by 102
Self-citationThe Media and Public Reaction to Genetic Research
Geller, G. (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.6.773 · Cited by 76
Representing a “revolution”: how the popular press has portrayed personalized medicine
Marcon, A. R., Bieber, M., & Caulfield, T. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.217 · Cited by 76
Self-citationMyriad and the mass media: the covering of a gene patent controversy
Caulfield, T., Bubela, T. M., & Murdoch, C. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31815bf965 · Cited by 71
Self-citation
Cited by
Human Germline and Heritable Genome Editing: The Global Policy Landscape
Baylis, F., Darnovsky, M., Hasson, K., & Krahn, T. M. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0082 · Cited by 155
“12 When relevant policies are mentioned, even in scholarly literature, the information provided is typically vague or inaccurate.”
Metadata
- Authors
- Marcon, A., Master, Z., Ravitsky, V., & Caulfield, T.
- Affiliations
- University of Alberta (CA)
- Mayo Clinic (US)
- Université de Montréal (CA)
- Corresponding author
- Caulfield, Timothy
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 21
- Issue
- 10
- Pages
- 2184-2189
- ISSN
- 1098-3600 (ISSN-L)
- PMC
- PMC6774996
- OpenAlex
- W2936337436
- Cited by
- 34
- References
- 15
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 2
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 785 d)
- Locations
- Genetics in Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Social Sciences › Communication › News Media Framing and Political Communication
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- CRISPR, media coverage, popular press, public perception, science communication, germline editing, ethical, legal and social implications, health benefits, risk perception, science policy
- MeSH terms
- Gene Editing, Animals, Humans, North America, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR in the North American popular press. https://app.cochat.ai/papers/10.1038/s41436-019-0482-5
- The paper
- Marcon, A., Master, Z., Ravitsky, V., & Caulfield, T. (2019). CRISPR in the North American popular press. Genetics in Medicine. https://doi.org/10.1038/s41436-019-0482-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.